T2747

Endothall is a protein phosphatase 2A (PP2A) inhibitor, capable of inhibiting PP2A (IC50: 90 nM) and PP1 (IC50: 5 uM). It acts as a herbicide and can also be useful in cancer chemotherapy.

GSK299115A (GSK-299115A) is a selective ROCK1 Inhibitor. GSK299115A exhibits IC50 of 8nM, 620nM, 560nM for ROCK1, RSK1, p70S6K, respectively.

GSK-2878175, a NS5B inhibitor, is used potentially for the treatment of HCV infection.

GSK317354A is a GRK2 inhibitor.

GSK-345931A (compound 3) is a potent and orally active RIP2 (receptor interacting protein 2) inhibitor that suppresses production of multiple pro-inflammatory cytokines, suitable for studying autoimmune diseases.

GSK356278 is an effective and selective inhibitor of phosphodiesterase 4 (PDE4), with pIC50s of 8.6, 8.8, and 8.7 for human PDE4A, PDE4B, and PDE4D, respectively. GSK356278 has anti-inflammatory, anxiolytic, and cognition-enhancing effects.

GSK360A is a novel prolyl hydroxylase (PHD) domain-containing enzyme inhibitor.

GSK3987 is an LXR ligand. GSK3987 recruits the steroid receptor coactivator-1 to human LXRalpha and LXRbeta with EC50s of 40 nM.

GSK466317A is a GRK2 inhibitor.